Laquinimod: A promising oral medication for the treatment of relapsing-remitting multiple sclerosis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 3, 2011, Pages 365-370

  Thöne, Jan ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

ABR 215062; immunomodulation; laquinimod; MS; Neuroprotection

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GILENYA; LAQUINIMOD; PLACEBO; ROQUINIMEX; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTHRALGIA; ARTICLE; ASTHENIA; BUDD CHIARI SYNDROME; COUGHING; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DOUBLE BLIND PROCEDURE (TOPIC); DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBRINOGEN BLOOD LEVEL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; INSOMNIA; LEIOMYOMA; MENORRHAGIA; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SIDE EFFECT; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUINOLONES; TREATMENT OUTCOME;

EID: 79951918131     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.556618     Document Type: Article

References (20)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
2. Lassmann H. Pathophysiology of inflammation and tissue injury in multiple sclerosis:What are the targets for therapy J Neurol Sci 2010. [Epub ahead of print]
3. Mangas A, Covenas R, Geffard M. New drug therapies for multiple sclerosis. Curr Opin Neurol 2010;23:287-92
4. Compston A, Confavreux C, McDonald I, et al. McAlpines Multiple sclerosis. 4th edition Churchill Livingstone Elsevier; Edinburgh 2006
5. Fugger L, Friese MA, Bell JI. From genes to function: the next challenge to understand multiple sclerosis. Nat Rev Immunol 2009;9:408-17
6. Noseworthy JH, Wolinsky JS, Lublin FD, Linomide in relapsing and secondary progressive MS. Part I: trial design and clinical results. Neurology 2000;54:1726-33 (Pubitemid 30428397)
7. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS. Part II: MRI results, MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide investigators. Neurology 2000;54:1734-41
8. Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3- quinolinecarboxamides for treatment of autoimmune disorders-activity relationship. J Med Chem 2004;47:2075-88 (Pubitemid 38453923)
9. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Laquinimod in relapsing MS Study Group. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64:987-91 (Pubitemid 40388448)
10. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92 (Pubitemid 351842581)
11. Comi G, Abramsky A, Arbizu T, et al. for the LAQ/5063 Study Group. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebocontrolled study. Multiple Sclerosis 2010;16:1360-6
12. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Exp Opin Investig Drugs 2009;18:985-9
13. Tuvesson H, Hallin I, Persson R, et al. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 2005;33:866-72 (Pubitemid 40686642)
14. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;30:163-72 (Pubitemid 35240003)
15. Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156:3-9
16. Wegner C, Stadelmann C, Pfortner, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demylination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;227:133-43
17. Zou LP, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacol 2002;42:731-9 (Pubitemid 34457755)
18. Gurevich M, Gritzman T, Orbach R, et al. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol 2010;221:87-94
19. Thone J, Seubert S, Conrad R, et al. Laquinimod induces up-regulation of BDNF in serum of patients with relapsing-remitting multiple sclerosis. Am Acad Neurol 2010;74(Suppl 2):A405
20. Thone J, Lee DH, Seubert S, et al. Laquinimod ameliorates experimental autoimmune encephalomyelitis via BDNF dependent mechanism. Multiple Sclerosis, 2010;16:P881